IN8bio
New York, New York, United States · Biotechnology, Therapeutics
IN8bio is a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for the treatment of cancer, leveraging its proprietary DeltEx platform to develop ex vivo–expanded, activated, and genetically modified cell therapies using allogeneic and autologous approaches. As the most clinically advanced company in this field, IN8bio combines deep expertise in gamma-delta T cell biol
Key facts
- Headquarters
- New York, New York, United States
- Employees
- 26
- Industries
- Biotechnology, Therapeutics
- Status
- Public (INAB)
- Website
- in8bio.com
- Company page
Recent activity at IN8bio
- : IN8bio Appoints Oxana Polyakova, Ph.D. as Senior Vice President of R&D
- : SEC 8-K (1.01): On June 1, 2026, IN8bio, Inc. entered into a Capital on Demand TM Sales Agreement with JonesTrading Institutional Services LLC, allowing the issuance and sale of shares of its common stock through an at-the-market offering program. Under this agreement, the Company can sell Placement Shares at its discretion, with the Agent receiving a 3% commission on the gross sales proceeds. The Sales Agreement may be terminated by either party with 10 days written notice. This agreement is notable as it suggests IN8bio's strategy to raise capital flexibly through equity financing, impacting its financial position and operational funding.
- : SEC 8-K (5.02): On May 7, 2026, the Company’s stockholders approved the Amended and Restated 2026 Equity Incentive Plan at the annual meeting. This plan, which replaces the 2023 Equity Incentive Plan, increases the shares available for issuance by 2,920,000 shares and extends the share increase period until 2037. Additionally, it sets a maximum of 20,000,000 shares for incentive stock options (ISOs) and adjusts the outside grant date for these ISOs to ten years from the adoption date. The strategic implication of this approval is to bolster the Company's equity-based compensation structure to attract and retain key talent.
- : SEC 8-K (5.02): On February 26, 2026, Alan S. Roemer announced his resignation from the Board of Directors of IN8bio, Inc., along with his roles on the Audit and Compensation Committees, effective February 28, 2026. This resignation was not due to any disagreement with the Company's management or Board. In his stead, Jeremy Graff has been appointed as the Interim Chair of the Board, effective February 28, 2026. The strategic implication of this change reflects a transition in leadership within the Board, aiming to maintain stability and continued governance oversight during this period of transition.
- : SEC 8-K (5.02):
- : IN8bio
- : SEC 8-K (1.01): On December 18, 2025, IN8bio, Inc. entered into a Securities Purchase Agreement with specified investors, agreeing to sell 5,127,029 shares of its common stock at $1.38 per share, along with pre-funded warrants for additional shares, with expected gross proceeds of approximately $20.1 million. The initial closing of this private placement is anticipated on or about December 22, 2025, subject to customary conditions. Furthermore, the agreement outlines potential additional sales during a second closing contingent on specific performance milestones related to the company's INB-619 product candidate, aiming for an additional $20.1 million in proceeds. These transactions signify a strategic funding effort by the company to bolster its financial resources for ongoing and future projects.
- : SEC 8-K (1.01): On December 18, 2025, IN8bio, Inc. entered into a Securities Purchase Agreement with certain investors to sell up to 5,127,029 shares of its common stock, par value $0.0001 per share. The agreement includes provisions for pre-funded warrants that allow the investors to purchase additional shares of common stock. The initial closing of this private placement is expected to take place on or about December 22, 2025, subject to customary closing conditions. This transaction potentially boosts the company's capital, enabling further investment into its business operations.
- : SEC 8-K (8.01): IN8bio, Inc. reported consolidated clinical data from its Phase 1 trial of INB-200 and Phase 2 trial of INB-400 during the 2025 Society for Neuro-Oncology Annual Meeting on November 21 and 22, 2025. The trials involved 17 patients treated with DeltEx DRI gamma-delta T cells, with 14 receiving multiple doses, achieving a median progression-free survival of 13.0 months compared to 6.6 months for those only on the standard of care. As of October 31, 2025, the median overall survival for patients on DeltEx DRI continues to increase and stands at 16.4+ months. This significant update provides insights into potential advancements in treating newly diagnosed glioblastoma, reflecting positively on the company's therapeutic strategies.
- : SEC 8-K (8.01): On October 27, 2025, IN8bio, Inc. announced the presentation of new preclinical data from its g d T cell engager (g d -TCE) program, INB-619, at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago. This announcement signifies a potential advancement in the Company's ongoing research and development efforts within the immunology space. The press release details the implications of the data for future clinical trials and treatment options, reflecting IN8bio's strategic commitment to innovation in therapeutic solutions. The event and disclosure aim to inform shareholders and potential investors of significant developments that could influence market perceptions and the Company's future performance.
IN8bio funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Venture | $20.1M |
| Oct 2024 | Venture | $12.4M |
| Dec 2023 | Venture | $35.0M |
| Dec 2023 | Post-IPO Equity | Undisclosed |
| Sep 2020 | Venture | $35.0M |
Leadership
- William Ho, Executive Officer, Director
- Thomas Cirrito, Director
- Travis Whitfill, Director
- Peter Brandt, Director
- Travis Whitfill, Director
- Thomas Cirrito, Director
- William Ho, Executive Officer, Director
- Travis Whitfill, Director
- Thomas Cirrito, Director
- William Ho, Executive Officer, Director
- Oxana Polyakova, Ph.D., Senior Vice President
- Lawrence Lamb, Executive Vice President
Verified email and direct lines for IN8bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
IN8bio in the news
- IN8bio to Present at Sidoti Small-Cap Virtual Conference - GlobeNewswire (Sep 22, 2026)
- IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences - Yahoo Finance (May 06, 2026)
- IN8bio’s Gamma-Delta T-cell Therapy INB-100 Helps Maintain Complete Remissions After HSCT in Patients With Hematologic Malignancies - CGTLive® (Jun 13, 2024)
- IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance (May 07, 2026)
- IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire (Sep 10, 2026)
- IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire (Aug 10, 2026)
- IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development - GlobeNewswire (Sep 09, 2026)
- IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference - GlobeNewswire (Dec 02, 2024)
Companies similar to IN8bio
- GenSight Biologics · Biotechnology, Therapeutics
- Nuvig Therapeutics · Biotechnology, Therapeutics
- Neogap Therapeutics · Biotechnology, Therapeutics
- Valink Therapeutics · Biotechnology, Therapeutics
- Mosaic Therapeutics · Biotechnology, Therapeutics
About IN8bio: questions and answers
What does IN8bio do?
IN8bio is a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for the treatment of cancer, leveraging its proprietary DeltEx platform to develop ex vivo–expanded, activated, and genetically modified cell therapies using allogeneic and autologous approaches. As the most clinically advanced company in this field, IN8bio combines deep expertise in gamma-delta T cell biol
Where is IN8bio headquartered?
IN8bio is headquartered in New York, New York, United States.
How many employees does IN8bio have?
IN8bio has about 26 employees.
Has IN8bio raised funding?
Yes. Fundz has recorded 5 funding events for IN8bio. The most recent, $20.1M, was in Dec 2025.
Who leads IN8bio?
Oxana Polyakova, Ph.D. is a Senior Vice President at IN8bio.
What is the latest news on IN8bio?
On Sep 09, 2026, IN8bio Appoints Oxana Polyakova, Ph.D. as Senior Vice President of R&D
Is IN8bio a public company?
Yes. IN8bio is publicly traded under the ticker INAB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy